Association between Tacrolimus Variability and ABCB1/CYP3A5 Genetic Polymorphisms in Kidney Transplant Recipients
References
- Shrestha BM. Two Decades of Tacrolimus in Renal Transplant: Basic Science and Clinical Evidences. Exp Clin Transplant. 2017 Feb;15(1):1–9. doi: 10.6002/ect.2016.0157.
- Thongprayoon C; Hansrivijit P; Kovvuru K et al, W. Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients. J. Clin. Med. 2020, 9, 2193. doi.org/10.3390/jcm9072193
- Chen Sh, Liu S, Yu L, Hou X, Zhao R, Factors and interventions affecting tacrolimus intrapatient variability: A systematic review and meta-analysis, Transplantation Rev (Orlando),2024,38(4):100878, doi.org/ 10.1016/j.trre.2024.100878
- Degraeve AL, Moudio S, Haufroid V, et al Predictors of tacrolimus pharmacokinnetik variability: current evidences and future perspectives. Expert Opinion on Drug Metabolism & Toxicology, 2020;16(9), 769–782. doi.org/10.1080/17425255.2020.1803277
- Cusinato, DAC, Lacchini R, Romao EA, Moysés-Neto M and Coelho EB. Relationship of CYP3A5 genotype and ABCB1 diplotypes to tacrolimus disposition in Brazilian kidney transplant patients. Br J Clin Pharmacol, 2014;78(2): 364–372. doi.org/10.1111/bcp.12345
- Pratt VM, Cavallari LH, Fulmer ML, et al. CYP3A4 and CYP3A5 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J Mol Diagn. 2023 Sep;25(9):619–629. doi: 10.1016/j.jmoldx.2023.06.008
- Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015 Jul;98(1):19–24. doi: 10.1002/cpt.113
- Tsironi A, Lazaros K, Mendrinou E, et; Impact of CYP3A4 and ABCB1 genetic variants on tacrolimus dosing in Greek kidney transplant recipients. Front. Pharmacol. 2025; 16:1538432. doi: 10.3389/fphar.2025.1538432
- Rotarescu CA, Maruntelu I, Rotarescu I, Constantinescu AE, Constantinescu I. Analysis of ABCB1 Gene Polymorphisms and Their Impact on Tacrolimus Blood Levels in Kidney Transplant Recipients. Int J Mol Sci. 2024;25(20):10999. doi: 10.3390/ijms252010999.
- Taneska-Canevska A, Trajceska L, Severova G, et al. Tacrolimus variability factors and interplay with kidney graft function. Journal of Morphological Sciences, 2025;8(2):40–49. doi: 1055302/JMS2582
- Trajceska L, Rambabova-Busletik, I Nikolov, et al. Tacrolimus variability in transplantation, Bantao Journal 2019 17:26–28
- Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(suppl 3): S1–S155. doi:10.1111/j.1600-6143.2009.02834.
- Wojciechowski D, Wiseman A. Long-term immunosuppression management: Opportunities and uncertainties. Clin J Am Soc Nephrol. 2021;16(8):1264–1271. doi:10.2215/CJN.15040920
- Xie W, Fan S, Liu R, et al;Tacrolimus intra-patient variability measures and its associations with allograft clinical outcomes in kidney transplantation. Transplant Rev (Orlando). 2024 38(3):100842. doi: 10.1016/j.trre.2024.100842.
- Shenoy MT, Manavalan J, A H, K S, Mohanty PK. Tacrolimus Concentration/Dose Ratio: A Tool for Guiding Tacrolimus Dosage Post- renal transplantation. Cureus. 2024;16(2): e53421. doi: 10.7759/cureus.53421.
- Park Y, Lee H, Eum SH, Ko EJ, Min JW, Yoon SH et al. Combined impact of the inter and intra-patient variability of tacrolimus blood level on allograft outcomes in kidney transplantation. Front Immunol. 2022 Nov16;13:1037566
- Davit BM, Chen ML, Conner DP, Haidar SH, Kim S, Lee CH, et al Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration. AAPS J. 2012 Dec;14(4):915–24
- Boenink R, Bonthuis M, Boerstra BA, et al, The ERA Registry Annual Report 2022: Epidemiology of Kidney Replacement Therapy in Europe, with a focus on sex comparisons, Clinical Kidney Journal, 2025;18(2): sfae405, doi.org/ 10.1093/ckj/
- Boenink R, Kramer A, Masoud S, Rodríguez-Benot A, et al. International comparison and time trends of first kidney transplant recipient characteristics across Europe: an ERA Registry study. Nephrol Dial Transplant. 2024;39(4):648–658. doi: 10.1093/ndt/gfad189.
- Stefanović NZ, Cvetković TP, Jevtović-Stoimenov TM, Ignjatović AM, Paunović GJ, Veličković RM. Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function. Exp Ther Med. 2015;10(3):1149–1156. doi: 10.3892/etm.2015.2598.
- Jakovski K, Kapedanovska Nestorovska A, Labacevski N, Dimovski A. Frequency of the most common CYP3A5 polymorphisms in the healthy population of the Republic of Macedonia. Maced Pharm Bull. 2012;5(1–2):25–30. doi 10.33320/maced.pharm.bull.2012.58.003.
- Naumovska Z, Nestorovska AK, Sterjev Z, Filipce A, Dimovski A, Suturkova L. Genotype variability and haplotype profile of ABCB1 (MDR1) gene polymorphisms in Macedonian population. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2014;35(3):121–33. doi: 10.1515/prilozi-2015-0016.
- Chauhan PM, Hemani RJ, Solanki ND, et al. A systematic review and meta-analysis recite the efficacy of Tacrolimus treatment in renal transplant patients in association with genetic variants of CYP3A5 gene. Am J Clin Exp Urol. 2023;11(4):275–292.
- Noble J et al; Improved Tacrolimus Therapeutic Drug Monitoring in Kidney Transplantation: Optimizing an Old Drug Prescription; Kidney International Reports, 2025;10(5):1326 – 1328. doi:10.1016/j.ekir.2025.02.019
- Leino AD, King EC, Jiang W, et al. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. Am J Transplant. 2019;19(5):1410–1420. doi: 10.1111/ajt.15199.
- Kurzawski M, Dąbrowska J, Dziewanowski K, Domański L, Perużyńska M, Droździk M. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. Pharmacogenomics. 2014;15(2):179–188. doi: 10.2217/pgs.13.199.
- Genvigir FDV, Salgado PC, Felipe CR, et al. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients. Pharmacogenet Genomics.2016;26(10): 462–72. doi: 10.1097/FPC.0000000000000237.
- Brazeau DA, Attwood K, Meaney CJ, et al. Beyond Single Nucleotide Polymorphisms: CYP3A536*7 composite and ABCB1 haplotype associations to tacrolimus pharmacokinetics in black and white renal transplant recipients; Front Genetics.2020;11:889; doi:10.3389/fgene.2020.00889.
DOI: https://doi.org/10.2478/bjmg-2026-0003 | Journal eISSN: 2199-5761 (formerly 1311-0160) | Journal ISSN: 1311-0160
Language: English
Page range: 23 - 32
Published on: Oct 14, 2026
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Related subjects:
© 2026 A Canevska Taneska, L Trajceska, I Rambabova Bushljetik, G Severova Andreevska, N Gjorgjievski, M Staninova Stojoska, P Dejanov, G Spasovski, Z Sterjev, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution 4.0 License.